Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $88 | In Stock | |
5 mg | $232 | In Stock | |
10 mg | $358 | In Stock | |
25 mg | $571 | In Stock | |
50 mg | $774 | In Stock | |
100 mg | $987 | In Stock | |
500 mg | $1,980 | In Stock | |
1 mL x 10 mM (in DMSO) | $355 | In Stock |
Description | Saroglitazar Magnesium is a novel peroxissome proliferator-activated receptor (PPAR) agonist with significant activation activity against PPARα (EC50 0.65pM) and moderate activation against PPARγ (EC50 3 nM). |
In vivo | In db/db mice, Saroglitazar (0.01-3 mg/kg per day, orally) treatment with 12-day causes dose-dependent reductions in serum triglycerides (TG), free fatty acids (FFA), and glucose. The ED50 for these effects is found to be 0.05, 0.19, and 0.19 mg/kg, respectively with highly significant (91%) reduction in serum insulin and AUC-glucose following oral glucose administration (59%) at 1 mg/kg dose.in Wistar rats and marmosets A 90-day repeated dose comparative study confirms efficacy (TG lowering) potential of Saroglitazar and has indicated low risk of PPAR-associated side effects in humans. Based on efficacy and safety profile, Saroglitazar appears to have good potential as novel therapeutic agent for treatment of dyslipidemia and diabetes[1]. |
Molecular Weight | 901.43 |
Formula | C50H56MgN2O8S2 |
Cas No. | 1639792-20-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 112.5 mg/mL (124.8 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.